Meningioma
Therapeutic area
Neurology
Rare disease
Yes
- Definition
- A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade I tumors, and some are WHO grade II or III tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Meningioma
- Therapeutic area
- Neurology
- meningioma
- meningioma (disease)
- meningothelial cell tumour
- primary meningeal tumour
- Severity
- Severe
- Neurology
- Oncology
Sources for recorded values
- MONDO ID
- MONDO:0016642
- Parent condition
- MONDO:0016743
Related records
Broader conditions (12)
- Cancer or benign tumor
- Central nervous system disorder
- Central nervous system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Nervous system disorder
- Nervous system neoplasm
- Tumor of meninges
Narrower conditions (83)
- Adult leptomeningeal melanoma
- Adult papillary meningioma
- Anaplastic meningioma
- Angiomatous meningioma
- Anterior cranial fossa meningioma
- Anterior foramen magnum meningioma
- Anterior optic tract meningioma
- Benign meningioma
- Bilateral meningioma of optic nerve
- Brainstem intraparenchymal clear cell meningioma
- Cavernous sinus meningioma
- Cerebellopontine angle meningioma
- Cerebral convexity meningioma
- Cerebral falx meningioma
- Cerebral meningioma
- Cervical spinal canal and spinal cord meningioma
- Childhood brain meningioma
- Chordoid meningioma
- Choroid plexus meningioma
- Clear cell meningioma
Trials (250)
- 177Lu-DOTATATE for Recurrent Meningioma
- 3D MRE-Based Evaluation of Meningioma Mechanical Properties and Histological Features
- 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
- 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
- 68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma
- 9-ING-41 in Pediatric Patients With Refractory Malignancies.
- A Comparative Study of Prophylactic Anticoagulation in Meningioma Surgery
- A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
- A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
- A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade Meningiomas
- A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
- A Study of ONC201 for Refractory Meningioma
- A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma
- A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
- A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas
- A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
- Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
- Abemaciclib in Newly Diagnosed Meningioma Patients
- Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
- Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
Drugs in development (49)
- Abemaciclib Phase 2
- Aldesleukin Phase 1
- Alpelisib Phase 1
- Aminolevulinic acid hydrochloride Phase 3
- Antineoplaston A10 Phase 2
- AR-42 Phase 2
- Avelumab Phase 1
- Bevacizumab Phase 2
- Brigatinib Phase 2
- Cabozantinib Phase 2
- Capivasertib Phase 2
- Dexamethasone Phase 2
- Dordaviprone Phase 1
- Edotreotide Phase 2
- Edotreotide gallium GA-68 Phase 2
- Erlotinib hydrochloride Phase 1
- Everolimus Phase 2
- Gefitinib Phase 2
- GSK-2256098 Phase 2
- Hydroxyurea Phase 2